Please assess the completion status of the following clinical trial:

Trial Title: Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent and authorization of use and disclosure of protected health information~* Age 50 years or older~* Presence of subretinal hemorrhage (SRH) involving the fovea in patients with NVAMD including polypoidal choroidal vasculopathy (PCV)~Exclusion Criteria:~* SFH in the study eye due to causes other than NVAMD~* Media opacity due to concurrent vitreous hemorrhage or cataracts that preclude adequate imaging~* Substantial loss of VA due to condition other than AMD~* Limited visual potential from substantial atrophy or fibrosis in fovea~* Poor visual potential with known permanent reduction in visual acuity prior to SFH

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-VEGF injection only (Type: None): Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
- Hemorrhage displacement + Anti-VEGF (Type: None): Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24

Based on this trial design, predict the completion outcome and termination type (if applicable).